


NEWSLETTER #1

Smart Surgical Solutions (S3) was fully established as a separate company on 18th February 2023 with licensed technology from Imperial College London. Mobile Assisted Reconstruction In Orthopaedics (M.A.R.I.O) is a revolutionary smartphone-based real-time surgical navigation system designed to help surgeons position an implant precisely. The last few months have seen numerous exciting developments and, given our dramatic progress, we have decided to produce our first newsletter to share our story with you. We hope that this is informative and we welcome the opportunity to connect and discuss further.



Recent highlights

Innovate UK funding

We have successfully secured £650k in funding from Innovate UK Biomedical Catalyst. This will provide crucial support for our ongoing development in the field of Machine Learning-based medical image segmentation, in collaboration with leading translational researchers at Imperial College London.

Seed investment

We reached the successful closure of our seed round investment, securing £160,000 from an angel investor who shares our vision. This investment will play a key role in supporting our ongoing development efforts and establishing a robust regulatory framework.

Technical development

We have successfully showcased the technology, including its physical implementation. To witness a live demonstration, please click the link [<here>](#).

Intellectual Property

Our technology has been protected through two distinct pieces of know-how, and a PCT patent was published in the summer of 2022.

The team

Three new members have joined our team this month.

Firstly, we have an exceptional App developer joining us who will be responsible for the development of our desktop planner and iOS app. His expertise will greatly contribute to enhancing our software offerings.



Secondly, we are pleased to have a QA/RA Engineer joining us. This individual will play a pivotal role in ensuring the documentation and compliance of our Quality Management System (QMS). She will leverage our well-established in-house QMS at Imperial College London.



Lastly, we are thrilled to introduce a highly accomplished post-doctoral research associate in machine learning to our team. This individual is based at Imperial College London and will contribute her expertise towards the development of automated medical image segmentation.



We are making significant strides in our product development and have set a target for FDA submission by the end of 2024. Furthermore, we have plans to conclude a Series A funding round by the beginning of 2024. If you are interested in exploring potential investment opportunities, we would be delighted to hear from you.

Thank you for reading our newsletter.

